牛牛AI助理已提取核心訊息
HOOKIPA Pharma Inc., a biotechnology company, has formally requested the United States Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, initially filed on December 22, 2023. The company is seeking to have the Registration Statement become effective on January 4, 2024, at 4:01 pm Eastern Time. This request was made under Rule 461 of the Securities Act of 1933. HOOKIPA Pharma's Chief Financial Officer, Reinhard Kandera, signed the request, indicating the company's awareness of its obligations under the Act. The company's outside counsel, Goodwin Procter LLP, will be available to address any questions from the SEC, with Finnbarr D. Murphy being the primary contact.
HOOKIPA Pharma Inc., a biotechnology company, has formally requested the United States Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, initially filed on December 22, 2023. The company is seeking to have the Registration Statement become effective on January 4, 2024, at 4:01 pm Eastern Time. This request was made under Rule 461 of the Securities Act of 1933. HOOKIPA Pharma's Chief Financial Officer, Reinhard Kandera, signed the request, indicating the company's awareness of its obligations under the Act. The company's outside counsel, Goodwin Procter LLP, will be available to address any questions from the SEC, with Finnbarr D. Murphy being the primary contact.
生物技術公司HOOKIPA Pharma Inc. 已正式要求美國證券交易委員會（SEC）加快其最初於2023年12月22日提交的S-3表格註冊聲明的生效日期。該公司正在尋求使註冊聲明於美國東部時間2024年1月4日下午 4:01 生效。該請求是根據1933年《證券法》第461條提出的。HOOKIPA Pharma的首席財務官萊因哈德·坎德拉簽署了該請求，表示該公司意識到該法案規定的義務。該公司的外部法律顧問古德溫·寶潔律師事務所將隨時解答美國證券交易委員會提出的任何問題，芬巴爾·墨菲是主要聯繫人。
生物技術公司HOOKIPA Pharma Inc. 已正式要求美國證券交易委員會（SEC）加快其最初於2023年12月22日提交的S-3表格註冊聲明的生效日期。該公司正在尋求使註冊聲明於美國東部時間2024年1月4日下午 4:01 生效。該請求是根據1933年《證券法》第461條提出的。HOOKIPA Pharma的首席財務官萊因哈德·坎德拉簽署了該請求，表示該公司意識到該法案規定的義務。該公司的外部法律顧問古德溫·寶潔律師事務所將隨時解答美國證券交易委員會提出的任何問題，芬巴爾·墨菲是主要聯繫人。
有用
沒用